Compare NNNN & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | ADNT |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | Germany | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2016 |
| Metric | NNNN | ADNT |
|---|---|---|
| Price | $26.00 | $24.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.85 |
| AVG Volume (30 Days) | 66.2K | ★ 955.4K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | $2.76 |
| Revenue Next Year | N/A | $2.24 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $5.91 | $10.04 |
| 52 Week High | $55.65 | $27.32 |
| Indicator | NNNN | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 50.32 |
| Support Level | $20.19 | $23.26 |
| Resistance Level | $31.92 | $25.83 |
| Average True Range (ATR) | 2.94 | 0.91 |
| MACD | 0.45 | -0.31 |
| Stochastic Oscillator | 52.24 | 6.34 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.